References
- Kapp AV, Jeffrey SS, Langerød A et al. Discovery and validation of breast cancer subtypes. BMC Genomics7, 231 (2006).
- Weigelt B, Mackay A, A’hern R et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol.11(4), 339–349 (2010).
- Gail MH, Brinton LA, Byar DP, Corle DK, Mulhivill JJ. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J. Natl Cancer Inst.81, 1879–1886 (1989).
- Santen RJ, Boyd NF, Chlebowski RT et al. Breast Cancer Prevention Collaborative Group. Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr. Relat. Cancer14(2), 169–187 (2007).
- Guo S, Russo IH, Russo J. Difference in gene expression profile in breast epithelial cells from women with different reproductive history. Int. J. Oncol.23, 933–941 (2003).
- King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science302, 643–646 (2003).
- Berstein LM. Endocrinology of the wild and mutant BRCA1 gene and types of hormonal carcinogenesis. Future Oncol.4(1), 23–39 (2008).
- Xue F, Michels KB. Intrauterine factors and risk of breast cancer: a systematic review and meta-analysis of current evidence. Lancet Oncol.8(12), 1088–1100 (2007).
- Park SK, Kang D, McGlynn KA et al. Intrauterine environments and breast cancer risk: meta-analysis and systematic review. Breast Cancer Res.10(1), R8 (2008).
- Salagame U, Canfell K, Banks E. An epidemiological overview of the relationship between hormone replacement therapy and breast cancer. Expert Rev. Endocrinol. Metab.6(3), 397–409 (2011).
- Daniel AR, Hagan CR, Lange CA. Progesterone receptor action: defining a role in breast cancer. Expert Rev. Endocrinol. Metab.6(3), 359–369 (2011).
- Horwitz KB, Sartorius CA. Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis. J. Clin. Endocrinol. Metab.93(9), 3295–3298 (2008).
- Asselin-Labat M-L, Lindeman GJ, Visvader JE. Mammary stem cells and their regulation by steroid hormones. Expert Rev. Endocrinol. Metab.6(3), 371–381 (2011).
- Eliassen AH, Hankinson SE. Endogenous hormone levels and risk of breast, endometrial and ovarian cancers: prospective studies. Adv. Exp. Med. Biol.630, 148–165 (2008).
- Simpson ER, Brown KA. Obesity, aromatase and breast cancer. Expert Rev. Endocrinol. Metab.6(3), 383–395 (2011).
- Leygue E, Murphy L. Comparative evaluation of ERα and ERβ significance in breast cancer: state of the art. Expert Rev. Endocrinol. Metab.6(3), 333–343 (2011).
- Hiscox S, Nicholson RI. Src kinase: a therapeutic opportunity in endocrine-responsive and resistant breast cancer. Expert Rev. Endocrinol. Metab.6(3), 423–435 (2011).
- Idelman G, Jacobson EM, Tuttle TR, Ben-Jonathan N. Lactogens and estrogens in breast cancer chemoresistance. Expert Rev. Endocrinol. Metab.6(3), 411–422 (2011).
- Miller WR. Markers of sensitivity, dependence and resistance to endocrine therapy for breast cancer. Expert Rev. Endocrinol. Metab.6(3), 345–357 (2011).
- Verma MK, Miki Y, Sasano H. Endocrine therapy after aromatase inhibitor therapy in breast cancer. Expert Rev. Endocrinol. Metab.6(3), 309–312 (2011).
- Carey LA. Through a glass darkly: advances in understanding breast cancer biology, 2000–2010. Clin. Breast Cancer10(3), 188–195 (2010).